Andrés José Maria Ferreri

44PUBLICATIONS
350CO-AUTHORS
Predictive and prognostic markersGene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Epidemiological methodsHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (44)

|Aug 31, 2026
Survival after first relapse in marginal zone lymphomas: Prospective data from the international observational NF10 study.

|Mar 28, 2026
Correction: Pourroy et al. High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European Registry. Cancers 2026, 18, 124.

Bertrand Pourroy, Maria D Aumente, Christian Koenecke

|Mar 15, 2026
Three-Hour Infusion of Methotrexate at 3 g/m2 With or Without Intrathecal Chemotherapy Significantly Reduces CNS Relapses and Improves Survival in Patients With Large B-Cell Lymphomas at Increased CNS Risk.

Andrés J M Ferreri, Federico Erbella, Piera Angelillo

|Jan 10, 2026
High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European Registry.

Bertrand Pourroy, Maria D Aumente, Christian Koenecke

|Jul 17, 2025
Prognostic gene expression and microRNA profiling signatures and genetic alterations in primary testicular diffuse large B-cell lymphoma.

Wenyu Shi, Zijun Y Xu-Monette, Youchao Jia

|May 22, 2025
B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements.

Gabriele Varano, Silvia Lonardi, Paola Sindaco

Pageof 8

Frequent Collaborators

8 joint publications

Teresa Calimeri

5 joint publications

Ken Young

5 joint publications

Alessandra Tucci

5 joint publications

Emanuele Zucca